Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial

Andrea Gallioli, Romain Boissier, Angelo Territo, Helena Vila Reyes, Francesco Sanguedolce, José Maria Gaya, Federica Regis, José Daniel Subiela, Joan Palou, Alberto Breda

Research output: Contribution to journalArticle

Abstract

Purpose: To address the safety and feasibility of adjuvant single-dose upper urinary tract instillation of mitomycin (ASDM) immediately after therapeutic ureteroscopy for upper tract urothelial carcinoma (UTUC) and to compare urothelial (ipsilateral or bladder) recurrence rates in the ASDM group and controls. Materials and Methods: Between April 2015 and August 2018, 52 patients affected by UTUC were treated by endoscopic ablation, of whom 26 were selected for ASDM. Clinical and perioperative data and 30-day complications were recorded. Urothelial recurrence-free survival (URFS) was evaluated with second-look ureteroscopy (URS) and CT scan/URS every 6 months. Results: ASDM was administered through a Single-J (19/25, 76%) or a Double-J (6/25, 24%) in 25/26 (96%) patients. Median follow-up was 18 months (IQR 10-29). The urothelial recurrence rate was 23.5% and 55.5% in the ASDM group and controls, respectively (p = 0.086). Mean URFS was 28.8 months in the ASDM group vs 18.8 months in controls (log-rank p = 0.067). On multivariate Cox regression, ASDM was associated with a 7.7-fold lower risk of urothelial recurrence (HR = 0.13; 95% CI 0.03-0.65; p = 0.01). Clavien grade ≤II complications occurred in 32% (8/25) and 30.7% (8/26) of the ASDM and control group, respectively (p = 0.9). Two Clavien III complications occurred in the ASDM group: bladder hematuria after concomitant transurethral resection of bladder and obstructive kidney failure in a single-kidney patient. Conclusions: ASDM was well tolerated after therapeutic URS. It appears to reduce the risk of urothelial recurrence in patients affected by low-grade UTUC without bladder tumor. Therefore, its use should be evaluated.

Original languageEnglish
Pages (from-to)573-580
Number of pages8
JournalJournal of Endourology
Volume34
Issue number5
DOIs
Publication statusPublished - May 1 2020
Externally publishedYes

Keywords

  • kidney-sparing surgery
  • mitomycin C
  • recurrence
  • topical chemotherapy
  • upper tract urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial'. Together they form a unique fingerprint.

  • Cite this

    Gallioli, A., Boissier, R., Territo, A., Vila Reyes, H., Sanguedolce, F., Gaya, J. M., Regis, F., Subiela, J. D., Palou, J., & Breda, A. (2020). Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. Journal of Endourology, 34(5), 573-580. https://doi.org/10.1089/end.2019.0750